A pilot randomized controlled clinical trial of Transcranial Alternating Current Stimulation in patients with multifocal pharmaco-resistant epilepsy

• Published in: Epilepsy & behavior 2022-05, Vol.130, p.108676-108676, Article 108676
• Main Authors: San-Juan, Daniel, Espinoza-López, Dulce Anabel, Vázquez-Gregorio, Rafael, Trenado, Carlos, Aragón, Maricarmen Fernández-González, Pérez-Pérez, Daniel, Hernández-Ruiz, Axel, Anschel, David J.
• Format: Article
• Language: English
• Subjects: Drug Resistant Epilepsy - therapy; Drug-resistant epilepsy; Humans; Multifocal epilepsy; Noninvasive neuromodulation; Pilot Projects; Seizures; tACS; Transcranial Alternating Current Stimulation; Transcranial Direct Current Stimulation - methods
• ISSN: 1525-5050; 1525-5069
• DOI: 10.1016/j.yebeh.2022.108676

Transcranial Alternating Current Stimulation (tACS) has therapeutic properties in network diseases. We hypothesize that tACS could be useful in the therapy of multifocal drug-resistant epilepsy. Although safe, we found no effect on seizure frequency reduction in patients receiving tACS. [Display omitted] •tACS is a safe noninvasive neuromodulation technique in humans.•tACS does not modify the seizure frequency in patients with multifocal epilepsy.•Patient and parameter selection are important factors for tACS efficacy. Transcranial Alternating Current Stimulation (tACS) is a promising noninvasive electrical stimulation therapy for neuropsychiatric diseases. Invasive neuromodulation using alternating current has been efficacious for drug-resistant epilepsy, but it is associated with surgical and medical complications. We aimed to explore the safeness and effectivity on seizure frequency reduction of two tACS protocols against placebo in patients with multifocal refractory epilepsy. This was a randomized, double-blinded, placebo-controlled clinical trial with 3-arm parallel-group (placebo, 30 min/2 mA daily sessions for 3 days [tACS-30], and 60 min/2 mA weekday sessions [tACS-60]). The main outcome was considered a change in reducing seizure frequency at 2 months after the intervention. Secondary outcomes were the apparition of any adverse effects during follow-up. At the second month, we observed a nonsignificant reduction in the seizure frequency in the placebo (7.3 ± 40.4%, p > 0.05) and the tACS-60 (26 ± 37.7%, p > 0.05). While the tACS-30 group showed a nonsignificant increase in seizure frequency (63.6 ± 155.3%, p > 0.05). No changes were statistically different from the placebo group. Otherwise, participants experienced only minor adverse events – the most common being an initial local transient tingling sensation (21%). This pilot study of tACS raises no severe safety issues, but provides negligible evidence for efficacy using this brief treatment protocol. Therefore, more studies are warranted testing different parameters to further verify the safety and effectivity of tACS in multifocal epilepsy.